Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 6, 2005, Pages 423-428

  Zambelli, A ^a   Lilleri, D ^b   Pedrazzoli, P ^c   Peccatori, J ^d   Baldanti, F ^b   Fregoni, V ^a   Ciceri, F ^d   Caldera, D ^b   Renga, M ^c   Colombo, A A ^b   Alessandrino, E P ^b   Gerna, G ^b   Da Prada, G A ^a   Siena, S ^c   Bregni, M ^d  

^a IRCCS   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Human cytomegalovirus infection; Nonmyeloablative allogeneic stem cell transplantation; Refractory solid tumor

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MELPHALAN; METHOTREXATE; PREDNISOLONE; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INCIDENCE; INFECTION RISK; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVARY CANCER; PROSPECTIVE STUDY; RECIPIENT; SARCOMA; SIBLING; SOLID TUMOR; STANDARDIZATION; VIREMIA; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGE FACTORS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 19944375833     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.02.005     Document Type: Article

References (26)

1. P.L. Weiden N. Flournoy E.D. Thomas et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts N Engl J Med 300 1979 1068-1073
2. M. Moscovitch S. Slavin Antitumor effect of allogeneic bone marrow transplantation in (NZB × NZW) F1 hybrids with spontaneous lymphosarcoma J Immunol 132 1984 997-1003
3. S. Morecki Y. Moshel Y. Gelfend T. Pugatsch S. Slavin Induction of graft vs. tumor effect in a murine model of mammary carcinoma Int J Cancer 71 1997 59-63
4. S. Morecki E. Yacovlev A. Diab S. Slavin Allogeneic cell therapy for murine mammary carcinoma Cancer Res 58 1998 3891-3895
5. B. Eibl H. Schwaighofer D. Nachbaur et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer Blood 88 1996 1501-1508
6. R. Childs A. Chernoff N. Contentin et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med 343 2000 750-758
7. M. Bregni A. Dodero J. Peccatori et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 99 2002 4234-4236
8. P. Pedrazzoli G.A. Da Prada G. Giorgiani et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies Cancer 94 2002 2409-2415
9. S. Slavin A. Nagler E. Naparstek et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic disease Blood 91 1998 756-763
10. C. Graber K.N. de Almeider R. Childs A.J. Barrett V.J. Gill J.E. Bennett CMV reactivation in nonmyeloablative HSCT Bone Marrow Transplant 27 2001 775
11. G. Gerna M.G. Revello E. Percivalle F. Morini Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia J Clin Microbiol 30 1992 1232-1237
12. G. Gerna E. Percivalle M. Torsellini M.G. Revello Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes J Clin Microbiol 36 1998 3585-3589
13. G. Gerna M.G. Revello E. Percivalle M. Zavattoni M. Parea M. Battaglia Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins J Clin Microbiol 28 1990 2681-2688
14. P. Ljungman P. Griffiths C. Paya Definitions of HCMV infection and disease in transplant recipients Clin Infect Dis 34 2002 1094-1097
15. M. Boeckh T.A. Gooley D. Myersion T. Cunningham G. Schoch R.A. Bowden Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study Blood 88 1996 4063-4071
16. H. Glucksberg R. Storb A. Fefer et al. Clinical manifestations of graft-versus-host-disease in human recipients of marrow from HLA-matched sibling donors Transplantation 18 1974 295-304
17. R. Martino M.D. Caballero C. Canals et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 28 2001 341-347
18. C. Junghanss K.A. Marr R.A. Carter et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study Biol Blood Marrow Transplant 8 2002 512-520
19. M. Mohty C. Faucher N. Vey et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation Bone Marrow Transplant 26 2000 251-255
20. S.B. Mossad R.K. Avery D.L. Longworth et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 28 2001 491-495
21. S. Chakrabarti S. Mackinnon R. Chopra et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution Blood 99 2002 4357-4363
22. P. Corradini C. Tarella A. Oliveri et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remission in patients with poor-risk hematologic malignancies Blood 99 2002 75-82
23. B.I. Rini T. Zimmerman W.M. Stadler T.F. Gajewski N.J. Vogelzang Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results J Clin Oncol 20 2002 2017-2024
24. P. Hentschke L. Barkholt M. Uzunel et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma Bone Marrow Transplant 31 2003 253-261
25. T.M. Friedman G. Varadi D.D. Hopely et al. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches Biol Blood Marrow Transplant 7 2001 656-664
26. S. Morecki Y. Gelfand A. Nagler et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen Bone Marrow Transplant 28 2001 243-249